Stockwinners Market Radar for November 29, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

16:01 EST EverQuote announces sudden passing of co-founder, CEO Seth Birnbaum - EverQuote issued the following statement: "It is with immeasurable sadness that we announce that Seth Birnbaum, Co-Founder and CEO, unexpectedly and peacefully passed away yesterday at his home. Seth was a sincere and deeply caring husband, father, friend and colleague. The entire EverQuote team mourns his tragic passing. On behalf of our Board of Directors, management team and employees, we extend our deepest sympathies to Seth's family. Seth was a genuine, dynamic leader whose remarkable passion, vision and tenacity attracted the world-class team we have in place today, which serves as the foundation for EverQuote's success. We will be forever grateful for his entrepreneurial spirit and the welcoming and caring environment he cultivated." The Board of Directors implemented the company's succession plan and appointed Jayme Mendal, the company's President, as its Chief Executive Officer and a member of the Board of Directors.

14:35 EST Aegon to sell Central, Eastern European business to VIG - Aegon has agreed to sell its insurance, pension and asset management business in Hungary, Poland, Romania and Turkey for EUR 830M to Vienna Insurance Group AG Wiener Versicherung Gruppe. The proceeds amount to EUR 830M and represent a multiple of 2.6 times the book value on June 30, 2020. This will result in an increase in IFRS equity of EUR 505M of which EUR 362M will be recognized as book gain based on the balance sheet position on June 30, 2020. The total net underlying earnings of Aegon's businesses in Central and Eastern Europe amounted to EUR 54M for 2019, implying a transaction multiple of 15 times net underlying earnings. As a result of the transaction, the Group Solvency II ratio is estimated to improve by approximately 8 percentage points. The proceeds will be upstreamed to the Group and increase Aegon's financial flexibility to execute on its strategic priorities, including deleveraging. On December 10, 2020, Aegon will provide an update on its strategy and financial targets at its virtual Capital Markets Day. The transaction is subject to regulatory and antitrust approvals customary for transactions of this nature and is expected to close in the second half of 2021.

14:26 EST Dr. Reddy's to acquire select anti-allergy brands from Glenmark - Dr. Reddy's announced that it has entered into a definitive agreement with Glenmark Pharmaceuticals to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino - for Russia, Kazakhstan and Uzbekistan -, Momat Rino Advance - for Russia -, Momat A - for Kazakhstan and Uzbekistan - , Glenspray and Glenspray Active - for Ukraine -, along-with rights to the trademarks, dossiers and patents for the territories mentioned. The acquired brands represent two types of products, mometasone mono product and combination of mometasone with azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.

14:20 EST Ziopharm comments on Institutional Shareholder Services' report - Ziopharm Oncology has issued a response to a report issued by Institutional Shareholder Services in connection with the consent solicitation initiated by WaterMill Asset Management, Robert Postma and certain other individuals. In its report, ISS recommends that Ziopharm shareholders reject WaterMill's attempt to remove half of the Ziopharm Board of Directors and to vote against the addition of Postma to the Board. Ziopharm "strongly recommends shareholders sign and return the Company's GREEN Consent Revocation Card." In a statement, the company said: "We are gratified that ISS acknowledges that removing half of Ziopharm's Board and replacing them with WaterMill's full slate of proposed candidates - including Mr. Postma, himself - would not be in the best interest of shareholders or the Company. In addition, we are pleased that ISS acknowledges the track record of Ziopharm's performance in recent years, which we believe underscores the long-term value potential in Ziopharm under the leadership of the current Board and management team. Importantly, while we have a great deal of respect for ISS, the report contains a number of factual mistakes. Additionally, key information in the public domain relating to WaterMill nominee Holger Weis raises questions regarding his suitability as a director." The company also said that Ziopharm's management team and Board believe "it is critical for shareholders to be aware of the following factual errors in the ISS report: ISS recommends in favor of fixing the Board size at seven, but their other recommendations would result in an eight-member board. ISS states that the Board "rejected" the resignations of Elan Ezickson and Dr. Scott Braunstein, but that is not correct. In fact, the Board never rejected these resignations. The Board promptly engaged two leading search firms to identify candidates in connection with the results of the 2020 annual meeting and has accepted resignations as soon as it has found suitable replacements. ISS reports Elan Ezickson attended 'fewer than 75 percent of meetings in 2019,' which is not accurate. Mr. Ezickson attended nearly 90% of Board and committee meetings in 2019. Mr. Ezickson attended fewer than 75% of meetings the year before that only because he was unable to participate in two special Board meetings that were called on short notice. ISS' review of Ziopharm's material weakness is incorrect. The ISS report notes 'there is nothing that prohibits the company from disclosing that remediation is underway,' when in fact Ziopharm has disclosed the remediation steps in several filings with the U.S. Securities and Exchange Commission, including in its most recent Form 10-Q filed on November 5, 2020. ISS also critiques the Board for the "retention of an overboarded director," but fails to note that the issue was remedied by the director's resignation from another board well in advance of the launch of the consent solicitation. Additionally, ISS recommends in favor of the election of WaterMill nominee Holger Weis arguing, among other things, that he 'served on a public company board.' However, the Company has not found any evidence that Mr. Weis has public company board experience, an assessment supported in WaterMill's own disclosures."

14:09 EST Cedar Realty Trust announces completion of 1-for-6.6 reverse stock split - Cedar Realty Trust announced the completion of its previously announced 1-for-6.6 reverse stock split of its common stock. Every 6.6 issued and outstanding shares of common stock have been converted into one share of common stock, effective prior to the opening of trading of the Company's common stock on November 27, 2020. As previously announced, stockholders received cash in lieu of fractional shares. Concurrently with the reverse stock split, the company's operating partnership subsidiary, Cedar Realty Trust Partnership, effected a corresponding 1-for-6.6 reverse split of its outstanding units of limited partnership interest. Fractional units were not redeemed in connection with this reverse unit split.